Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Mastech Digital, Inc.Mastech Digital Reports Slight Revenue Decline in Q2 2025, Net Income Drops
CREATIVE REALITIES, INC.Creative Realities Reports $1.8 Million Net Loss and Revenue Decline for Q2 2025
URBAN ONE, INC.Urban One Reports 22.2% Revenue Decline and Increased Operating Loss in Q2 2025
Savara IncSavara Inc. Reports $30.4 Million Net Loss in Q2 2025, Increases R&D Spending for MOLBREEVI
Indaptus Therapeutics, Inc.Indaptus Therapeutics Reports Increased Net Loss and Decreased Total Assets for Q2 2025
Ovid Therapeutics Inc.Ovid Therapeutics Reports $6.4M Revenue Growth Amid $14.9M Net Loss in Latest Filing
Worksport LtdWorksport Ltd. Reports 114% Revenue Growth in Q2 2025 Despite Net Loss
ARTELO BIOSCIENCES, INC.Artelo Biosciences Reports Increased Net Loss and Deteriorating Financial Position for First Half of 2025
Wilhelmina International, Inc.Wilhelmina International Reports Mixed Financial Results for Q2 2025
Adaptimmune Therapeutics PLCAdaptimmune Reports 89% Revenue Decline and $30.3 Million Net Loss in Latest Quarter
DUKE Robotics Corp.DUKE Robotics Reports $143,000 Revenue in Q2 2025, Net Loss of $548,000
Tourmaline Bio, Inc.Tourmaline Bio Reports $23.1 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses
Sagimet Biosciences Inc.Sagimet Biosciences Reports $10.4 Million Net Loss in Q2 2025, Driven by Rising Operating Expenses
SideChannel, Inc.SideChannel Reports Q3 Revenue Decline and Continued Net Losses
Aura Biosciences, Inc.Aura Biosciences Reports $27M Net Loss in Q2 2025, Increases R&D Spending
Charlotte's Web Holdings, Inc.Charlotte's Web Holdings Reports 4.2% Revenue Growth in Q2 2025
SBC Medical Group Holdings IncSBC Medical Group Reports Revenue Decline and Profitability Challenges in Q2 2025
ProMIS Neurosciences Inc.ProMIS Neurosciences Reports $10.1 Million Net Loss in Q2 2025 Amid Rising R&D Expenses
Instil Bio, Inc.Instil Bio Reports $21.4 Million Net Loss for Q2 2025, Increased Operating Expenses
Perspective Therapeutics, Inc.Perspective Therapeutics Reports Increased Operating Losses and Declining Grant Revenue in Q2 2025
ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Reports $15.7M Revenue and $44.9M Net Loss for Quarter Ending June 30, 2025
CROWN CRAFTS INCCrown Crafts Reports $1.1 Million Net Loss and Decrease in Sales for Quarter Ending June 29, 2025
Galera Therapeutics, Inc.Galera Therapeutics Reports $2.7 Million Net Loss, Workforce Reduction and Strategic Acquisition
ESSA Pharma Inc.ESSA Pharma Reports $4M Loss for Nine Months Ending June 30, 2025, Amid Strategic Transition
i-80 Gold Corp.i-80 Gold Corp. Reports $27.8 Million Revenue and Significant Financial Improvements